Proteasome inhibitors such as bortezomib exhibit clinical efficacy in multiple myeloma but studies in acute myeloid leukemia (AML) have been disappointing to date. The apparent failure in AML likely reflects a lack of biological understanding that might clarify applications of proteosome inhibitors in this disease. Here we show that AML cells are considerably less sensitive than control non-cancerous cells to bortezomib-induced cytotoxicity, permitting most bortezomib-treated AML cells to survive treatment. We traced reduced bortezomib sensitivity to increased basal levels of nuclear Nrf2, a transcription factor that stimulates protective antioxidant enzymes. Bortezomib stimulates cytotoxicity through accumulation of reactive oxygen species (ROS) but elevated basal levels of nuclear Nrf2 present in AML cells reduced ROS levels, permitting AML cells to survive drug treatment. We further found that the Nrf2 transcriptional repressor Bach1 is rapidly inactivated by bortezomib, allowing rapid induction of Nrf2-regulated cytoprotective and detoxification genes which protect AML cells from bortezomib-induced apoptosis. By contrast, non-malignant control cells lacked constitutive activation of Nrf2, such that bortezomib-mediated inactivation of Bach1 led to a delay in induction of Nrf2-regulated genes, effectively preventing the manifestation of apoptotic protection that is seen in AML cells. Together, our findings argue that AML might be rendered sensitive to proteasome inhibitors by co-treatment with either an Nrf2-inhibitory or Bach1-inhibitory treatment, rationalizing a targeted therapy against AML.
Introduction
Acute myeloid leukemia (AML) comprises a heterogeneous group of clonal disorders of hematopoietic progenitors, showing genetic instability and characterized by proliferation and differentiation of abnormal cells, causing accumulation of immature myeloid cells in bone marrow and blood. Five-year survival varies from 15-70% depending on clinical and biological factors, with overall AML survival rates for all patients diagnosed with the disease being less than 20% (1) . Furthermore, with 75% of patients diagnosed after the age of 60, current intensive therapeutic strategies are generally limited to a minority of younger, fitter patients. There is a significant unmet need for better tolerated, more widely applicable targeted anti-AML therapy (2) .
Recently, a number of potential new systemic anti-cancer therapies (SACT) have emerged that are targeted to specific signaling pathways or cellular processes aimed at blocking proliferation and inducing apoptosis (3) . Many potential SACTs are being evaluated but their roles, efficacies and modes of action as either single agents or combined with other drugs are yet to be fully defined. One such pathway which is being targeted is the ubiquitin-proteasome system that controls protein turnover and many cellular processes, including cell cycle, gene regulation, and oxidative stress responses. NF-E2-related factor 2 (Nrf2) and nuclear factor-κB (NF-κB) are two transcription factors regulated by the ubiquitin-proteasome system (4, 5) . Both NF-κB and Nrf2 activate survival pathways known to play important roles in protecting malignant cells from SACT cytotoxicity (6, 7) . AML cells show aberrant or constitutive NF-κB activation (8) , with a central step being phosphorylation and proteasomedependent degradation of its inhibitory proteins (IκBs), possible targets for proteasome inhibitors in aberrant elevated NF-κB found in certain cancers.
The role of Nrf2 in AML-resistance to proteasome inhibition has not been investigated. Nrf2 functions to rapidly change the sensitivity of a cell's environment to oxidants and electrophiles by stimulating the transcriptional activation of over a hundred cytoprotective genes, including antioxidants ferritin, glutathione-S-reductase (GSR), and glutamyl cysteine ligase-modulator (GCLM) and -catalytic (GCLC), phase-I drug oxidation enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1), and cytoprotective enzyme heme oxygenase-1 (HO-1) genes (9) . With respect to HO-1, other transcription factors including NF-κB and AP-1 are also involved in its expression (10) (11) (12) . Under normal physiological conditions, the inhibitor of Nrf2, Keap1, mediates ubiquitin-26S proteasomal degradation of Nrf2. Oxidative and electrophilic stresses such as reactive oxygen species (ROS) or SACTs, impairs Keap1-mediated proteasomal degradation of Nrf2, causing Nrf2 activation and subsequent nuclear translocation (10) . Nuclear Nrf2 forms a heterodimer complex with Maf proteins which bind the antioxidant response element (ARE) located in the enhancer regions of Nrf2-inducible genes. Therefore, side effects of proteasome inhibition may be increased cellular Nrf2 leading to its activation, and up-regulation of cytoprotective proteins. However, a regulatory process exists to control nuclear Nrf2 activation in the form of the transcriptional repressor Bach1, bound to ARE enhancer regionsin cells naïve to oxidative stress to block Nrf2 binding. Bach1 becomes deactivated and translocates to the cytosol, upon pro-oxidant stimuli (13) .
We recently showed in AML that high basal NF-κB levels regulate expression of HO-1 and that upon NF-κB inhibition, HO-1 levels increase and protect AML cells from apoptosis via inhibition of ROS formation (12) . The present study was undertaken to define the role of HO-1 and Nrf2 in response to the only clinically-approved proteasome inhibitor, bortezomib. Bortezomib is already used for effective treatment of multiple myeloma and mantle cell lymphoma and is well tolerated clinically. With regards to AML, a small number of clinical trials have been conducted with proteasome inhibitors revealing relatively disappointing results (14) (15) (16) . The present studies were undertaken to investigate the mechanism by which treating AML with proteasome inhibitors alone is ineffective.
Materials and Methods

Materials
AML-derived cell lines THP-1 and HL60 were obtained from ECACC (Salisbury, UK) where they are authenticated by DNA-fingerprinting. In the laboratory they are used at low passage number for a maximum of 6 months postresuscitation, testing regularly for Mycoplasma infection. Antibodies were sourced from Assay Designs (HO-1), Abcam (Bach1), Santa Cruz Biotechnology (all others). Control, HO-1, Nrf2, Bach1 and Keap1 siRNA were from Applied Biosystems. Dead cells were removed from samples using Dead-Cert Nanoparticles (ImmunoSolv, UK). Other reagents were from Sigma-Aldrich unless indicated.
Cell culture
Primary AML cells were obtained under local ethical approval (LREC ref 07/H0310/146). For primary cell isolation PBMCs and monocytes were isolated from healthy donors as described (12) . Selection of human hematopoietic stem cells were isolated from PBMCs using a CD34+ selection kit (Miltenyi Biotec, Auburn, CA). For all experiments at least three different donors were used to obtain the results presented. AML samples <80% blasts expressing CD34, were purified using the CD34+ selection kit. Cell type was confirmed by microscopy and flow cytometry.
RNA extraction and real-time PCR
Total RNA was extracted from 5 x 10 5 cells using the Nucleic acid PrepStation from Applied Biosystems, according to the manufacturer's instructions.
Reverse transcription was performed as described previously (12) using the specific primers:
Gene ID Forward Reverse
ChIP assays
THP-1 cells were treated as described (12) 
Western immunoblotting, binding assay and flow cytometry
SDS-PAGE and Western analyses were performed as described (17) . Cytosolic and nuclear extracts were prepared as described (18) . Flow cytometry for measuring apoptosis was performed on an Accuri-C6 flow cytometer. A dichlorofluorescein (DCF) assay was used to determine cellular ROS generation in AML cells (19, 20) . 
Determination of intracellular glutathione levels
To detect intracellular glutathione levels, 1x10 4 HL60 and THP-1 cells were seeded in 96-well cell culture dishes and allowed to grow for 24 h. Cells were then incubated with bortezomib for up to 24 h. Intracellular glutathione levels were quantified using the bioluminescent GSH-Glo™ glutathione assay (Promega).
Statistical analyses
Student's t test was performed. P < 0.05 was considered statistically significant (*).
Results represent mean ± SEMs of 3 independent experiments. For Western blotting experiments, data are representative of 3 independent experiments.
Results
AML cell sensitivity to proteasome inhibition.
To understand the mechanism by which AML cells resist apoptosis in response to the proteasome inhibitor bortezomib (21-23), we analysed the response of AML patient samples (Table 1) , AML cell lines and non-malignant control cells to increasing concentrations of bortezomib. Figure 1A shows 
Bortezomib induces cytoprotective and detoxification gene expression in AML cells.
A potential role for antioxidant behaviour (24, 25) of bortezomib was investigated.
Under normal physiological conditions Keap1 mediates the ubiquitin-26S
proteasome-mediated degradation of Nrf2 (10, 26) and regulates redox-sensitive activation of Nrf2 (26, 27) . As the generation of ROS is now considered to be the early critical event for initiation of bortezomib-induced apoptosis in some cancer cells Figure 4) with additional NF-κB inhibition possibly also needed (12) in regard to bortezomib-induced AML death. These findings show that basal nuclear Nrf2 is responsible for protecting AML cells from bortezomib-induced apoptosis and the mechanism by which Nrf2 is protecting AML cells is via combined upregulation of cytoprotective and detoxifying genes, and not directly mediated through HO-1.
Bortezomib inhibits Bach1/ARE in AML paving the way for Nrf2 activation
To further understand the significance of constitutive nuclear Nrf2 activity in AML cells, we analysed the expression of the Nrf2 transcriptional repressor Bach1. 
Bortezomib induces ROS to activate Nrf2 and Bach1, protecting AML from apoptosis
Since Keap1 regulates redox-sensitive activation of Nrf2 (26), and ROS are considered critical in bortezomib-induced effects in some cancer cell lines (28,29), the role of ROS was examined here in AML. In response to bortezomib treatment, ROS generation occurred in a time-dependent manner ( Figure 5A ). ROS activation kinetics correlate with nuclear accumulation of Nrf2 following bortezomib ( Figure 3B ).
Moreover, we observed a secondary decrease in ROS levels in bortezomib-resistant AML cells (AML217, AML306, THP-1) apparent 2-8 h after treatment, that was not observed in more bortezomib-sensitive cells (CD34+, AML303, AML205)( Figure 5A ).
Comparing these data, there are two clear groupings: (i) those cells sensitive to bortezomib and without a secondary reduction in ROS levels; and (ii) cells that are insensitive to bortezomib with a substantial secondary reduction in ROS levels. Next we examined the role of Nrf2 in regulating ROS levels in AML cells. Figure 5B shows that if we inhibit Nrf2 expression and activation using an Nrf2 siRNA., in Interestingly, other proteasomal inhibitors like MG132 preferentially induce apoptosis in AML cells over non-malignant control cells (31). However, peptidyl aldehydes such as MG132 are less specific than bortezomib as they inhibit serine/cysteine proteases in addition to the proteasome, with poorer stability and bioavailability (32), and therefore are less likely to become clinically useful. Bacterial product lactacystin is more proteasome-specific, however irreversibly blocks several proteasomal proteolytic activities, whereas bortezomib reversibly inhibits more the chymotrypsinlike activities. These unique features of bortezomib make it easier to administer in an in vivo setting and result in its decreased toxicity. However, as we and others have discovered, using better targeted proteasome inhibitors like bortezomib leads to no preferential apoptosis in AML cells over control cells (14, 15, 22) . We show here Figure 7) .
Moreover, based on these observations, the identification of small molecules that potently and specifically inhibit the Nrf2-dependent response or prevent ROSdependent Bach1 activation would be extremely important in increasing the efficacy of new and existing proteasomal inhibitors for therapeutic applications, particularly in AML.
One of the main questions to be raised by this study is why is Nrf2 constitutively active in some but not all AML cells and not in control cells? This is not the first time that Nrf2 has been shown to be constitutively active in human cancer cells (45, 48) .
In human lung cancer tissues and lung carcinoma lines, mutation in the inhibitor of Nrf2, Keap1, inactivated its repressor function causing Nrf2 activation as demonstrated by elevated Nrf2 protein levels, Nrf2 nuclear localization and increased mRNA expression of Nrf2 target genes. Moreover, Nrf2 was found to be increased in 91.5% of tumors from patients with head and neck squamous cell carcinoma, plus abnormally elevated Nrf2 protein levels were observed in pancreatic cancer tissues and cell lines, resulting in their increased drug resistance (49) .
Therefore, it is highly likely that cancer cells acquire growth advantage during the course of transformation by either eliminating any Keap1-mediated negative control of Nrf2, or by increasing Nrf2 protein levels to the point which Keap1 is saturated, subsequently leading to better activation of Nrf2-dependent defence responses.
Further work to determine why Nrf2 is abnormally high in AML is underway, as understanding this mechanism may pave the way to developing combinational therapies for the treatment of AML.
Our results clearly indicate that the Nrf2-dependent defence response helps survival of AML cells during treatment with bortezomib. It is also clear that Nrf2-dependent protection accounts for drug sensitivity of AML cells to bortezomib. Drug sensitivity to SACT is the major obstacle to the successful treatment of many cancers including neuroblastoma, breast cancers and lung cancers. In the course of SACT, a strong initial response is frequently followed by the appearance of drug-resistant variants.
Moreover, many genes reported to play roles in drug sensitivity seemingly have functional links with Nrf2. For instance, Nrf2 is a key regulator of phase II-detoxifying enzyme NQO1. In addition, Nrf2 regulates many of the key enzymes important in maintaining cellular redox homeostasis, such as GCLC and GCLM which are the rate-limiting enzymes controlling glutathione biosynthesis. Moreover, GSR facilitates the reduction of glutathione disulfide to the sulfhydryl form of glutathione. Therefore, since Nrf2 regulates many genes including HO-1 to provide reduced sensitivity towards proteasomal inhibition, targeting Nrf2 may be more effective than targeting any of these genes alone. In conclusion, our data demonstrate that inhibition of Nrf2 sensitizes cells to proteasome inhibition, suggesting that Nrf2 inhibitors may be used concomitantly to increase the efficacy of anticancer therapy. Lipopolysaccharide-induced heme oxygenase-1 expression in human using density gradient and in some instances CD34+ positive selection (* denotes isolated through CD34 positive selection. ** denotes % of blasts and promyelocytes).
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